COVID-19 is an emerging, rapidly evolving situation.

NCI Central Institutional Review Board (CIRB) Guidance for the New Coronavirus: https://www.ncicirb.org/

FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic Guidance for Industry, Investigators, and Institutional Review Boards

MEMORANDUMS

• 
  Date: May 8, 2020
• Additional Guidance Regarding Reporting of Minor Deviations for Clinical Trials (PDF, 89.66 KB)  Supported by the NCI DCP Phase 0-2 Cancer Prevention Clinical Trials Program
  Date: March 27, 2020
• Guidance for Collection of Adverse Events Related to COVID-19 Infection (PDF, 41.9 KB)
  Date: March 25, 2020
• Additional Guidance for Clinical Trial Activities Affected by the Novel Coronavirus (PDF, 148.24 KB)
  Date: March 23, 2020
• Interim Guidance for Patients on Clinical Trials Supported by the NCI CTEP and NCORP (PDF, 146.64 KB)
  Date: March 13, 2020
• Interim Guidance for Patients on Clinical Trials Supported by the NCI DCP Phase 0-2 Cancer Prevention Clinical Trials Program (PDF, 83.66 KB)
  Date: March 13, 2020

Last updated: May 8, 2020